Long-term study of EB-1020 for children with ADHD
Part of Mental health clinical trials.
This trial tests a new medication, EB-1020, over a longer period in children with ADHD. It aims to see if the drug continues to be safe and effective beyond the initial 6-week treatment. Some participants may have already been in a previous EB-1020 study, while others are new.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a child or teenager (age not specified, but pediatric) with a primary diagnosis of ADHD (not another condition that looks like ADHD).
- Your ADHD symptoms must be at least moderately severe, based on a standard rating scale.
- You cannot have certain other mental health conditions like Tourette's, panic disorder, conduct disorder, psychosis, PTSD, bipolar disorder, or untreated generalized anxiety.
- You cannot have autism spectrum disorder, or a primary diagnosis of oppositional defiant disorder or obsessive-compulsive disorder.
- You cannot have an IQ below 70 or a current major depressive episode (unless it has been well managed for at least 3 months).
- You must not have any lab results that are too low/too high (like low platelets or high liver enzymes) or use prohibited medications during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (EB-1020) for children with ADHD. It aims to see if the drug is safe and effective in reducing ADHD symptoms.
This trial is for adults with ADHD who completed a previous study of the drug EB-1020. It tests the long-term safety and effectiveness of the medication over an extended period.
This trial tests a new medication called EB-1020 for adults with ADHD. It aims to see if the drug is safe and effective in improving ADHD symptoms. You may be able to join if you have a clear ADHD diagnosis and your symptoms are moderate to severe.
This trial tests starting a new medication (Methylphenidate or Guanfacine) in young children with moderate or severe ADHD to see how well it works and if it’s safe.
This trial tests if a mixed amphetamine medication helps teenagers with both autism and ADHD who still have significant symptoms, even if they are already on other treatments. It also includes typically developing teens as a comparison group.
This trial tests a study medication (dexamfetamine) for adults who have both ADHD and moderate to severe depression. It aims to see if the medication is safe and helps improve both conditions.
Hear when a new Attention-Deficit Hyperactivity Disorder(ADHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.